Correlation Between Novartis and UBS Group

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Novartis and UBS Group at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novartis and UBS Group into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Novartis AG and UBS Group AG, you can compare the effects of market volatilities on Novartis and UBS Group and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novartis with a short position of UBS Group. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novartis and UBS Group.

Diversification Opportunities for Novartis and UBS Group

-0.5
  Correlation Coefficient

Very good diversification

The 3 months correlation between Novartis and UBS is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Novartis AG and UBS Group AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UBS Group AG and Novartis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novartis AG are associated (or correlated) with UBS Group. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UBS Group AG has no effect on the direction of Novartis i.e., Novartis and UBS Group go up and down completely randomly.

Pair Corralation between Novartis and UBS Group

Assuming the 90 days trading horizon Novartis AG is expected to under-perform the UBS Group. But the stock apears to be less risky and, when comparing its historical volatility, Novartis AG is 1.45 times less risky than UBS Group. The stock trades about -0.15 of its potential returns per unit of risk. The UBS Group AG is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest  2,597  in UBS Group AG on August 30, 2024 and sell it today you would earn a total of  170.00  from holding UBS Group AG or generate 6.55% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Novartis AG  vs.  UBS Group AG

 Performance 
       Timeline  
Novartis AG 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novartis AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.
UBS Group AG 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in UBS Group AG are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, UBS Group may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Novartis and UBS Group Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Novartis and UBS Group

The main advantage of trading using opposite Novartis and UBS Group positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novartis position performs unexpectedly, UBS Group can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UBS Group will offset losses from the drop in UBS Group's long position.
The idea behind Novartis AG and UBS Group AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Money Managers
Screen money managers from public funds and ETFs managed around the world
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world